Five months project extension

04 October 2017

In agreement with the European Lead Factory partners, the Innovative Medicines Initiative (IMI) has agreed with a no-cost extension of the term of the ELF project to the end of May 2018.

‘This will allow us to maximise the impact for the public screening programmes.’ Ton Rijnders, ELF Head of Screening and Scientific Director Lygature, explained. ‘We estimate that we now can finish almost all programmes enrolled to date in the European Lead Factory.’

In addition, it will have an effect on the number and use of the novel compounds in the Joint European Compound Library. ‘Over the years, more than 1000 library designs have been submitted. The extra months will permit us to fully exploit the wealth of chemical innovation, to incorporate the novel compounds in the screening collection and increase their likelihood to be found as actives against a drug target.’ Dimitrios Tzalis, ELF Head of Chemistry and Founder & CEO of Taros, said.

Stefan Jaroch, ELF coordinator and Head of External Innovation Technologies Bayer, confirmed ‘Evaluating the progress and closely monitoring the budget, we realised that we could make a big change by using the remaining funding over a few more months.’

Are you interested in submitting a drug target to the European Lead Factory? Please contact the Programme Office.